Mark your calendars as our team heads to two upcoming investor conferences. Learn more:  https://t.co/K4x2LLqKjS  #CellTherapy #CRISPR $CRBU

Caribou Biosciences $CRBU said Monday that its off-the-shelf CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma. The study results, while preliminary, are comparable to benchmarks set by currently approved, patient-specific CAR-T

We are excited to share data from the ANTLER trial showing that vispa-cel (CB-010), an allogeneic CAR-T cell therapy for patients with non-Hodgkin lymphoma, drives deep and durable responses on par with the autologous CAR-Ts. 🔗Join webcast at 8:00 am ET: https://t.co/o9lInIwceQ

Don't change your current workflow. Tembo meets you where you are.

We are excited to share the first clinical data from the Phase 1 CaMMouflage trial of CB-011 in patients with multiple myeloma — showing deep, durable responses with a manageable safety profile. 🔗 Webcast at 8:00 am ET here: https://t.co/5uAw5ucJ52

Join $CRBU tomorrow morning as the company shares data from the ANTLER and CaMMouflage phase 1 clinical trials. Conference call and webcast to be hosted at 8:00am ET. Link to webcast here: https://t.co/6TanSqGYto

Caribou Biosciences is heading to #IMS2025. We are leading the way for multiple myeloma treatment by advancing CB-011, an allogeneic CAR-T cell therapy designed to be scalable, off-the-shelf, and accessible. #Myeloma #CellTherapy $CRBU

Don't miss the fireside chat tomorrow with our president and CEO, Rachel Haurwitz, PhD, at the @Citi Biopharma Back to School Conference. Tune into the webcast here: https://t.co/G2IP6Ix6zZ #CellTherapy #CRISPR $CRBU

$CRBU is headed to the @Citi Biopharma Back to School Conference next week. See you in Boston.  Learn more: https://t.co/MdyAofaPPG #CellTherapy #CRISPR

We’re excited to share that Caribou Biosciences will be participating in the @LLSusa Light The Night event in San Francisco this November! Join us in supporting this incredible cause. https://t.co/JZyq09AELr #LightTheNight #CaribouCares

Today we reported our Q2 earnings. Learn more in our second quarter 2025 financial results and business update: https://t.co/XT9yxO7VMq #CRISPR #CellTherapy $CRBU

Joining us for #EHA2025? Members of our clinical team will be in attendance for the conference. We’re excited to see you in Milan and connect with the clinical hematology community. #CRISPR #CARTCellTherapy #Lymphoma $CRBU

Heading to Boston? Join Caribou’s SVP of translational research, Enrique Zudaire, PhD, as he chairs a session about optimizing dosing & enhancing therapeutic outcomes at the 7th Annual Allogeneic Cell Therapies Summit. Learn more: https://t.co/ir8GmvNqwX #CRISPR #CARTCellTherapy

Tune in to a fireside chat tomorrow with our president and CEO, Rachel Haurwitz, PhD, at the @Jefferies Global Healthcare Conference. Tune into the webcast here: https://t.co/R4ISLXfKxy #CellTherapy #CRISPR $CRBU

See you at #ASCO25! Members of our clinical and translational team will be in attendance. We’re looking forward to connecting with clinical leaders in #Lymphoma and #MultipleMyeloma to discuss our ongoing ANTLER and CaMMouflage clinical trials. #CRISPR #CARTCellTherapy

We’re headed to the @Jefferies Global Healthcare Conference next week for a fireside chat. Learn more: https://t.co/y6jHH8bS3j

Today we reported our Q1 earnings. Learn more in our first quarter 2025 financial results and business update: https://t.co/RkXVLtnH1K #CRISPR #CellTherapy $CRBU

Tune into the webcast with Rachel Haurwitz, PhD, at BofA Securities 2025 Health Care Conference. Read here for more details: https://t.co/KXOCicb9o5 $CRBU

Caption: Caribou continues to see encouraging data from lead clinical programs in oncology, CB-010 for 2L LBCL and CB-011 for r/r #multiplemyeloma, and has taken actions to prioritize allocation of resources for these two Phase 1 clinical programs. $CRBU https://t.co/oCOsIdfa0M

According to @theNCI, #multiplemyeloma affects ~179,000 people in the U.S., with ~36,000 new patients diagnosed each year. At Caribou, we’re leading a new era of #CARTcelltherapies and patient care for multiple myeloma. Learn more: https://t.co/m1k1atCUpv

This Wednesday, our VP of technical operations will present at the BioProcess International US West Conference. For more details and a full schedule, head to the event site: https://t.co/EsdWmIvKaY